<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B27A8418-A71E-4A7F-9AFD-DF6317A9B658"><gtr:id>B27A8418-A71E-4A7F-9AFD-DF6317A9B658</gtr:id><gtr:name>Biovation UK Limited</gtr:name><gtr:address><gtr:line1>c/o Kpmg Llp 37 Albyn Place</gtr:line1><gtr:city>Aberdeen</gtr:city><gtr:postCode>AB10 1JB</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B27A8418-A71E-4A7F-9AFD-DF6317A9B658" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B27A8418-A71E-4A7F-9AFD-DF6317A9B658</gtr:id><gtr:name>Biovation UK Limited</gtr:name><gtr:address><gtr:line1>c/o Kpmg Llp 37 Albyn Place</gtr:line1><gtr:city>Aberdeen</gtr:city><gtr:postCode>AB10 1JB</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24312.0</gtr:offerGrant><gtr:projectCost>42498.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D7AD109B-B07C-4A35-9361-908334B759D3"><gtr:id>D7AD109B-B07C-4A35-9361-908334B759D3</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Everingham</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700367"><gtr:id>A2BFE67A-2738-4CE6-A69D-A07C6BA1C810</gtr:id><gtr:title>Novel Advanced Orthopaedic Instrumentation for Synthetic Cartilage Implants</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700367</gtr:grantReference><gtr:abstractText>Biovation UK Limited would like to further research &amp;amp; investigate the large joint (L.J) market
and aims to develop the Cartiva synthetic cartilage implant (SCI) instrumentation. The Cartiva
SCI currently distributed by Biovation UK Limited is used to replace warn or damaged
cartilage in Hallux (toe) joints, but the current instrumentation used to perform the procedure
has downfalls. There is currently limited effective treatment of focal defects in L.J?s. SCI
could be a favoured operative technique as it has an excellent recovery rate, after 48 hours a
patients joint can be weight bearing. SCI has the potential to be minimally invasive (much less
invasive than total joint replacement, TJR), it is an intermediate treatment which would
postpone the need for TJR ?this type of treatment with the correct indications &amp;amp; future
implant &amp;amp; instrumentation improvements... may guarantee a several year period of knee
health &amp;amp; active life style.? (F.V. Sciarretta 2013). This means that in older patients SCI could
potentially eradicate patients that have had TJR needing revisionary surgery. Biovation UK
Limited would like to investigate a potential gap in the market &amp;amp; develop an easier to use,
minimally invasive, single use instrumentation, with hopes to advance the current
instrumentation to aid in implantation of the SCI as a remedy for chondral focal lesions in
L.J?s. In England &amp;amp; Wales there are approx 160K total knee replacements performed
annually (National Joint Registry, 2013). ?As recent papers have demonstrated chondral
lesions can be encountered in up to 67% of knee arthoscopies? (F.V. Sciarretta 2013). The
knee joint medical market is by far the largest, most lucrative market globally. SCI is most
suited to chondral focal lesions, in 993 consecutive arthroscopies; 66% of cases show
incidence where a surgical approach is needed &amp;amp; 20% of cases show focal lesions that would
benefit from SCI (Am J Sports Med 2004).</gtr:abstractText><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24312</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700367</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>